EUVIMEDEUVIMED entdecken
Crossref

Iberdomide: First Approval

Hannah A Blair

Drugs · 10.11.2026

DOI: 10.1007/s40265-026-02417-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drugs, online erschienen am 10.11.2026. Verfasst von Hannah A Blair. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com. Die Arbeit nennt 46 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iberdomide (ZENBEXUS™) is a cereblon E3 ligase modulator being developed by Bristol Myers Squibb and its subsidiary Celgene Corporation for the treatment of various haematological malignancies, including multiple myeloma. On 13 August 2026, iberdomide received accelerated approval in the USA for use in combination with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. On 30 September 2026, iberdomide received conditional approval in China for use in combination with daratumumab and dexamethasone to treat adult patients with multiple myeloma who have received at least one first-line therapy (including a proteasome inhibitor and an immunomodulatory agent). This article summarizes the milestones in the development of iberdomide leading to this first approval for multiple myeloma.

Autor:innen und Institutionen

  • Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Zitieren

APA

Blair, H. A. (2026). Iberdomide: First Approval. Drugs. https://doi.org/10.1007/s40265-026-02417-8

Vancouver

Blair HA. Iberdomide: First Approval. Drugs. 2026. doi:10.1007/s40265-026-02417-8

BibTeX
@article{Blair2026,
  author = {Blair, Hannah A},
  title = {Iberdomide: First Approval},
  journal = {Drugs},
  year = {2026},
  doi = {10.1007/s40265-026-02417-8}
}
Kostenlos starten →